{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-387197","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2026-09-10T11:05:24+00:00","discovered_at":"2026-09-10T11:10:00.683068+00:00","generated_at":"2026-09-10T11:10:47.287410+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"EyePoint posts updated investor presentation with LUGANO Phase 3 data; specifics not disclosed in excerpt","bullets":["EyePoint posted an updated investor presentation on September 10, 2026, on its website.","Presentation titled 'LUGANO Phase 3 Clinical Trial DURAVYU in Wet AMD Expanded Results & Analyses'.","No specific efficacy, safety, or financial figures are included in the provided excerpt.","DURAVYU is being studied for wet age-related macular degeneration in the LUGANO Phase 3 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-387197","json":"https://secwatch.observer/filing/0001193125-26-387197.json","markdown":"https://secwatch.observer/filing/0001193125-26-387197.md","text":"https://secwatch.observer/filing/0001193125-26-387197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/0001193125-26-387197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-20260910.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-10T11:10:47.287410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}